Use of ivermectin in the treatment of COVID-19: a review

Detalhes bibliográficos
Autor(a) principal: Zanoti, Eduardo Bertollini
Data de Publicação: 2022
Outros Autores: Porto, Rodrigo Magalhães, Scriboni, Andreia Borges
Tipo de documento: Artigo
Idioma: eng
Título da fonte: MedNEXT Journal of Medical and Health Sciences
Texto Completo: https://mednext.zotarellifilhoscientificworks.com/index.php/mednext/article/view/130
Resumo: Introduction: SARS-CoV-2 produces a respiratory syndrome that can range from a mild, self-limiting inflammatory condition to severe, progressive pneumonia. Prevention and treatment strategies have become a priority since the emergence of COVID-19. Noteworthy is the use of ivermectin, an anti-parasitic agent, which has been widely recommended by some health professionals for the prevention and treatment of COVID-19. Objective: To assess the evidence on the efficacy and safety of using ivermectin for the prevention and treatment of COVID-19, identifying its mode of action and the benefits and adverse reactions of using this drug. Methods: The search strategy for articles was based on a search in the electronic databases MEDLINE (NationalLibrary of Medicine, United States), LILACS (Latin American and Caribbean Literature in Health Sciences), Scielo, specialized libraries of Universities, PubMed, and Google Academic. The selected articles will be from 2015 to 2021. Results and Conclusion: Studies reveal that ivermectin is a broad-spectrum drug with high-fat solubility and has numerous effects on several parasites. In addition to having antiviral and antiparasitic effects, this drug also causes immunomodulation in the host. Ivermectin has already demonstrated its potent antiviral effects in vitro against several RNA viruses, such as influenza A, Zika virus, Newcastle disease virus, yellow fever virus, Chikungunya virus, dengue virus, among others. One way to delay viral transmission would be to stop the virus from replicating, thus reducing the viral load in infected individuals. Thus, studies have shown that ivermectin may have the potential for inhibiting and replicating SARS-CoV-2.
id FACERES-1_b72925c7fced7ce9128d871dba01ae0f
oai_identifier_str oai:ojs2.mednext.zotarellifilhoscientificworks.com:article/130
network_acronym_str FACERES-1
network_name_str MedNEXT Journal of Medical and Health Sciences
repository_id_str
spelling Use of ivermectin in the treatment of COVID-19: a reviewCOVID-19SARS-CoV-2IvermectinTreatmentPreventionIntroduction: SARS-CoV-2 produces a respiratory syndrome that can range from a mild, self-limiting inflammatory condition to severe, progressive pneumonia. Prevention and treatment strategies have become a priority since the emergence of COVID-19. Noteworthy is the use of ivermectin, an anti-parasitic agent, which has been widely recommended by some health professionals for the prevention and treatment of COVID-19. Objective: To assess the evidence on the efficacy and safety of using ivermectin for the prevention and treatment of COVID-19, identifying its mode of action and the benefits and adverse reactions of using this drug. Methods: The search strategy for articles was based on a search in the electronic databases MEDLINE (NationalLibrary of Medicine, United States), LILACS (Latin American and Caribbean Literature in Health Sciences), Scielo, specialized libraries of Universities, PubMed, and Google Academic. The selected articles will be from 2015 to 2021. Results and Conclusion: Studies reveal that ivermectin is a broad-spectrum drug with high-fat solubility and has numerous effects on several parasites. In addition to having antiviral and antiparasitic effects, this drug also causes immunomodulation in the host. Ivermectin has already demonstrated its potent antiviral effects in vitro against several RNA viruses, such as influenza A, Zika virus, Newcastle disease virus, yellow fever virus, Chikungunya virus, dengue virus, among others. One way to delay viral transmission would be to stop the virus from replicating, thus reducing the viral load in infected individuals. Thus, studies have shown that ivermectin may have the potential for inhibiting and replicating SARS-CoV-2.Faceres2022-02-22info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/otherapplication/pdfhttps://mednext.zotarellifilhoscientificworks.com/index.php/mednext/article/view/13010.54448/mdnt22107MedNEXT Journal of Medical and Health Sciences; Vol. 3 No. 1 (2022): MedNEXTMedNEXT Journal of Medical and Health Sciences; v. 3 n. 1 (2022): MedNEXT2763-567810.54448/mdnt221reponame:MedNEXT Journal of Medical and Health Sciencesinstname:Faculdade de Medicina em São José do Rio Preto (Faceres)instacron:FACERESenghttps://mednext.zotarellifilhoscientificworks.com/index.php/mednext/article/view/130/128Copyright (c) 2022 MedNEXT Journal of Medical and Health Scienceshttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessZanoti, Eduardo BertolliniPorto, Rodrigo MagalhãesScriboni, Andreia Borges2022-02-22T20:29:09Zoai:ojs2.mednext.zotarellifilhoscientificworks.com:article/130Revistahttps://mednext.zotarellifilhoscientificworks.com/index.php/mednextPUBhttps://mednext.zotarellifilhoscientificworks.com/index.php/mednext/oaimednextjmhs@zotarellifilhoscientificworks.com2763-56782763-5678opendoar:2022-02-22T20:29:09MedNEXT Journal of Medical and Health Sciences - Faculdade de Medicina em São José do Rio Preto (Faceres)false
dc.title.none.fl_str_mv Use of ivermectin in the treatment of COVID-19: a review
title Use of ivermectin in the treatment of COVID-19: a review
spellingShingle Use of ivermectin in the treatment of COVID-19: a review
Zanoti, Eduardo Bertollini
COVID-19
SARS-CoV-2
Ivermectin
Treatment
Prevention
title_short Use of ivermectin in the treatment of COVID-19: a review
title_full Use of ivermectin in the treatment of COVID-19: a review
title_fullStr Use of ivermectin in the treatment of COVID-19: a review
title_full_unstemmed Use of ivermectin in the treatment of COVID-19: a review
title_sort Use of ivermectin in the treatment of COVID-19: a review
author Zanoti, Eduardo Bertollini
author_facet Zanoti, Eduardo Bertollini
Porto, Rodrigo Magalhães
Scriboni, Andreia Borges
author_role author
author2 Porto, Rodrigo Magalhães
Scriboni, Andreia Borges
author2_role author
author
dc.contributor.author.fl_str_mv Zanoti, Eduardo Bertollini
Porto, Rodrigo Magalhães
Scriboni, Andreia Borges
dc.subject.por.fl_str_mv COVID-19
SARS-CoV-2
Ivermectin
Treatment
Prevention
topic COVID-19
SARS-CoV-2
Ivermectin
Treatment
Prevention
description Introduction: SARS-CoV-2 produces a respiratory syndrome that can range from a mild, self-limiting inflammatory condition to severe, progressive pneumonia. Prevention and treatment strategies have become a priority since the emergence of COVID-19. Noteworthy is the use of ivermectin, an anti-parasitic agent, which has been widely recommended by some health professionals for the prevention and treatment of COVID-19. Objective: To assess the evidence on the efficacy and safety of using ivermectin for the prevention and treatment of COVID-19, identifying its mode of action and the benefits and adverse reactions of using this drug. Methods: The search strategy for articles was based on a search in the electronic databases MEDLINE (NationalLibrary of Medicine, United States), LILACS (Latin American and Caribbean Literature in Health Sciences), Scielo, specialized libraries of Universities, PubMed, and Google Academic. The selected articles will be from 2015 to 2021. Results and Conclusion: Studies reveal that ivermectin is a broad-spectrum drug with high-fat solubility and has numerous effects on several parasites. In addition to having antiviral and antiparasitic effects, this drug also causes immunomodulation in the host. Ivermectin has already demonstrated its potent antiviral effects in vitro against several RNA viruses, such as influenza A, Zika virus, Newcastle disease virus, yellow fever virus, Chikungunya virus, dengue virus, among others. One way to delay viral transmission would be to stop the virus from replicating, thus reducing the viral load in infected individuals. Thus, studies have shown that ivermectin may have the potential for inhibiting and replicating SARS-CoV-2.
publishDate 2022
dc.date.none.fl_str_mv 2022-02-22
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
info:eu-repo/semantics/other
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://mednext.zotarellifilhoscientificworks.com/index.php/mednext/article/view/130
10.54448/mdnt22107
url https://mednext.zotarellifilhoscientificworks.com/index.php/mednext/article/view/130
identifier_str_mv 10.54448/mdnt22107
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://mednext.zotarellifilhoscientificworks.com/index.php/mednext/article/view/130/128
dc.rights.driver.fl_str_mv Copyright (c) 2022 MedNEXT Journal of Medical and Health Sciences
https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2022 MedNEXT Journal of Medical and Health Sciences
https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Faceres
publisher.none.fl_str_mv Faceres
dc.source.none.fl_str_mv MedNEXT Journal of Medical and Health Sciences; Vol. 3 No. 1 (2022): MedNEXT
MedNEXT Journal of Medical and Health Sciences; v. 3 n. 1 (2022): MedNEXT
2763-5678
10.54448/mdnt221
reponame:MedNEXT Journal of Medical and Health Sciences
instname:Faculdade de Medicina em São José do Rio Preto (Faceres)
instacron:FACERES
instname_str Faculdade de Medicina em São José do Rio Preto (Faceres)
instacron_str FACERES
institution FACERES
reponame_str MedNEXT Journal of Medical and Health Sciences
collection MedNEXT Journal of Medical and Health Sciences
repository.name.fl_str_mv MedNEXT Journal of Medical and Health Sciences - Faculdade de Medicina em São José do Rio Preto (Faceres)
repository.mail.fl_str_mv mednextjmhs@zotarellifilhoscientificworks.com
_version_ 1796798219917721600